Figure 1 / 10



No of erection/10min
(60min post dose)
2.5
2.0
1.5
1.0
0.5
0.0
B
0.1
1
10
100
Dose (ug/kg sc)

Figure 2 / 10



Number of erections/10minutes
(30-40 minutes post dose)
2.5
2.0
1.5
1.0
0.5
0.0
Vehicle
1
10
100
Dose (μg kg-1 s.c.)

Figure 3 / 10

ORTEP plot for the crystal structure of the compound of Example 5




Figure 4 / 10

ORTEP plot for the crystal structure of the compound of Preparation 16




Figure 5 / 10

ORTEP plot for the crystal structure of the compound of Preparation 22b





Figure 6 / 10

ORTEP plot for the asymmetric unit of the crystal structure of (3S,4R)-4-(2,4-difluorophenyl)-N-[(1R)-1-phenylethyl]pyrrolidine-3-carboxamide hydrochloride



Simulated PXRD Pattern for Compound of Example 5




Figure 8 / 10

Simulated PXRD Pattern for Compound of Preparation 16




Figure 9 / 10

Simulated PXRD Pattern for Compound of Preparation 22b




Figure 10 / 10

Simulated PXRD Pattern for (3S,4R)-4-(2,4-difluorophenyl)-N-[(1R)-1-phenylethyl]pyrrolidine-3-carboxamide hydrochloride

